Supplementary Figure 5 from Detection of Brain Tumor Cells in the Peripheral Blood by a Telomerase Promoter-Based Assay

MacArthur, Kelly M.; Kao, Gary D.; Chandrasekaran, Sanjay; Alonso-Basanta, Michelle; Chapman, Christina; Lustig, Robert A.; Wileyto, E. Paul; Hahn, Stephen M.; Dorsey, Jay F.

doi:10.1158/0008-5472.22402601.v1

00085472can130813-sup-fig5.pdf (106 kB)

Supplementary Figure 5 from Detection of Brain Tumor Cells in the Peripheral Blood by a Telomerase Promoter-Based Assay

journal contribution

posted on 2023-03-30, 22:34 authored by Kelly M. MacArthur, Gary D. Kao, Sanjay Chandrasekaran, Michelle Alonso-Basanta, Christina Chapman, Robert A. Lustig, E. Paul Wileyto, Stephen M. Hahn, Jay F. Dorsey

PDF file - 105KB, Supplementary Figure 5. Comparison of EGFR-expressing CTCs from additional patients with EGFR over-expressing high grade glioma and EGFR (-) glioma tumors.

History

ARTICLE ABSTRACT

Blood tests to detect circulating tumor cells (CTC) offer great potential to monitor disease status, gauge prognosis, and guide treatment decisions for patients with cancer. For patients with brain tumors, such as aggressive glioblastoma multiforme, CTC assays are needed that do not rely on expression of cancer cell surface biomarkers like epithelial cell adhesion molecules that brain tumors tend to lack. Here, we describe a strategy to detect CTC based on telomerase activity, which is elevated in nearly all tumor cells but not normal cells. This strategy uses an adenoviral detection system that is shown to successfully detect CTC in patients with brain tumors. Clinical data suggest that this assay might assist interpretation of treatment response in patients receiving radiotherapy, for example, to differentiate pseudoprogression from true tumor progression. These results support further development of this assay as a generalized method to detect CTC in patients with cancer. Cancer Res; 74(8); 2152–9. ©2014 AACR.